Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:LNTH NASDAQ:NRIX NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.66-1.9%$27.72$14.32▼$36.28$6.70B0.761.65 million shs730,882 shsLNTHLantheus$96.77-2.5%$85.66$47.25▼$103.89$6.33B-0.03955,572 shs227,872 shsNRIXNurix Therapeutics$17.44-1.8%$16.22$8.19▼$22.50$1.81B1.861.12 million shs338,661 shsPCVXVaxcyte$49.41-3.9%$55.92$29.08▼$65.00$7.13B1.241.41 million shs420,110 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant0.00%-2.49%+22.65%+20.00%+123.94%LNTHLantheus0.00%-3.59%+17.35%+30.14%+31.51%NRIXNurix Therapeutics0.00%+1.49%+6.35%+12.33%+67.23%PCVXVaxcyte0.00%+8.67%-10.20%-17.07%+57.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.66-1.9%$27.72$14.32▼$36.28$6.70B0.761.65 million shs730,882 shsLNTHLantheus$96.77-2.5%$85.66$47.25▼$103.89$6.33B-0.03955,572 shs227,872 shsNRIXNurix Therapeutics$17.44-1.8%$16.22$8.19▼$22.50$1.81B1.861.12 million shs338,661 shsPCVXVaxcyte$49.41-3.9%$55.92$29.08▼$65.00$7.13B1.241.41 million shs420,110 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant0.00%-2.49%+22.65%+20.00%+123.94%LNTHLantheus0.00%-3.59%+17.35%+30.14%+31.51%NRIXNurix Therapeutics0.00%+1.49%+6.35%+12.33%+67.23%PCVXVaxcyte0.00%+8.67%-10.20%-17.07%+57.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3314.31% UpsideLNTHLantheus 2.73Moderate Buy$101.865.26% UpsideNRIXNurix Therapeutics 2.93Moderate Buy$30.4674.69% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0074.05% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, IMVT, PCVX, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/18/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ALNTHLantheus$1.54B4.09$6.22 per share15.55$16.43 per share5.89NRIXNurix Therapeutics$83.98M21.47N/AN/A$5.29 per share3.30PCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1523.4218.02N/A18.05%29.32%15.00%8/5/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-411.37%-64.21%-48.44%7/9/2026 (Estimated)PCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)Latest NRIX, IMVT, PCVX, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/8/2026Q1 2026NRIXNurix Therapeutics-$0.76-$0.79-$0.03-$0.79$14.25 million$6.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09LNTHLantheus0.472.832.64NRIXNurix TherapeuticsN/A6.016.01PCVXVaxcyteN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%LNTHLantheus99.06%NRIXNurix TherapeuticsN/APCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%LNTHLantheus1.70%NRIXNurix Therapeutics6.70%PCVXVaxcyte3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionablePCVXVaxcyte160144.40 million139.63 millionOptionableNRIX, IMVT, PCVX, and LNTH HeadlinesRecent News About These CompaniesWhy Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments2 hours ago | finance.yahoo.comVaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical TrialsMay 30 at 9:32 AM | finance.yahoo.comVaxcyte Inc Ordinary Shares PCVXMay 28, 2026 | morningstar.comMVaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine RulesMay 28, 2026 | msn.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 21, 2026 | americanbankingnews.comVaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlookMay 20, 2026 | quiverquant.comQAnalysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX) and Cross Country Healthcare (CCRN)May 18, 2026 | theglobeandmail.comabrdn Healthcare Investors Q1 2026 CommentaryMay 15, 2026 | seekingalpha.comVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comVaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund DMay 11, 2026 | marketbeat.comNan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVXMay 10, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Misses Estimates By $0.56 EPSMay 6, 2026 | marketbeat.comVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comVaxcyte, Inc. $PCVX Shares Purchased by UBS Group AGMay 6, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Down 6.8% - What's Next?May 5, 2026 | marketbeat.comVanguard Group Inc. Sells 126,467 Shares of Vaxcyte, Inc. $PCVXMay 5, 2026 | marketbeat.comJennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVXMay 2, 2026 | marketbeat.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comIs It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?April 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRIX, IMVT, PCVX, and LNTH Company DescriptionsImmunovant NASDAQ:IMVT$32.66 -0.64 (-1.92%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Lantheus NASDAQ:LNTH$96.77 -2.53 (-2.55%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Nurix Therapeutics NASDAQ:NRIX$17.44 -0.32 (-1.82%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Vaxcyte NASDAQ:PCVX$49.41 -1.99 (-3.87%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Alphabet Bets on Hardware With Googlebook and AI Glasses Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
